Login
$NVAX
$8.07 +$0.01 (0.12%) After hours

Company Executives

Officer Age 2025 pay Source
JOHN C. JACOBS Also a director
President and CEO
Title from the Form 4 dated Mar 3, 2026
59 $8,856,015
JAMES P. KELLY
EVP, CFO and Treasurer
Title from the Form 4 dated Mar 7, 2026
Not stated $2,986,228
ELAINE O’HARA
EVP, Chief Strategy Officer
Title from the Form 4 dated Mar 3, 2026
Not stated $3,688,276
MARK J. CASEY
EVP, Chief Legal Officer
Title from the Form 4 dated Mar 3, 2026
Not stated $2,810,453
ROBERT WALKER
Executive Vice President, Research & Development
Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
9
serving now
Independent
8 of 9
stated in the proxy
Average tenure
5.7 years
from year joined
CEO also chairs the board
No
David Mott
Director Age On board Independent Committees Other public boards 2025 pay Source
David Mott
60 2020
6 years
Independent
Compensation · Chair
Ardelyx $365,591
John C. Jacobs
59 2023
3 years
Not independent None stated None stated Paid as CEO
Gregg H. Alton, J.D.
60 2020
6 years
Independent
Audit Nominating and Corporate Governance Capital Allocation
Corcept Therapeutics $355,091
Richard J. Rodgers
59 2022
4 years
Independent
Compensation Capital Allocation
Ardelyx, Inc. $375,449
Richard H. Douglas, Ph.D.
73 2010
16 years
Independent
Audit Research and Development
Alderya Therapeutics, Inc. $364,462
Margaret G. McGlynn, R.Ph.
66 2020
6 years
Independent
Nominating and Corporate Governance · Chair
Amicus Therapeutics $402,278
Rachel K. King
66 2018
8 years
Independent
Compensation Nominating and Corporate Governance
Fulcrum Therapeutics $353,091
John W. Shiver, Ph.D.
68 2025
1 year
Independent
Compensation Research and Development · Chair
None stated $516,545
Charles W. Newton
55 2025
1 year
Independent
Audit Nominating and Corporate Governance Capital Allocation · Chair
Coherus Oncology $491,949

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Apr 27, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support